NCT07416474 2026-04-20
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
RemeGen Co., Ltd.
Phase 3 Recruiting
Clinical Trials
31 trialsNCT07502300 2026-04-20
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03967977 2026-04-17
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
BeOne Medicines
Phase 3 Active not recruiting
NCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT06745908 2026-04-15
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Recruiting
NCT04164199 2026-04-14
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT07383116 2026-02-03
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT07170995 2025-11-18
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT04170283 2025-10-21
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT04921358 2025-06-29
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT04746924 2025-06-24
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeiGene
Phase 3 Active not recruiting
NCT05840016 2025-05-02
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Akeso
Phase 3 Active not recruiting
NCT06416410 2025-04-04
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03358875 2025-02-10
RATIONALE-303
BeiGene
Phase 3 Completed
NCT03663205 2025-02-04
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03924986 2025-01-31
RATIONALE-309
BeiGene
Phase 3 Completed
NCT04866017 2024-10-31
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03594747 2024-10-26
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
BeiGene
Phase 3 Completed
NCT05990127 2023-08-14
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Akeso
Phase 3 Not yet recruiting
NCT05791097 2023-07-24
AdvanTIG-306
Novartis
Phase 3 Withdrawn
NCT05564338 2023-06-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
Phase 3 Withdrawn
NCT05718167 2023-02-14
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT03745222 2020-07-15
RATIONALE001
Celgene
Phase 3 Terminated